Search This Blog

Tuesday, June 2, 2026

Rezolute positive interim Phase 3 as 6 of 8 tumor hyperinsulinism patients meet primary endpoint

 

Rezolute reports positive interim Phase 3 upLIFT data as 6 of 8 tumor hyperinsulinism patients on ersodetug meet primary endpoint

  • All 6 responders discontinued IV glucose following ersodetug treatment in tumor hyperinsulinism, based on interim upLIFT data.
  • Topline Phase 3 upLIFT results for ersodetug are expected in the second half of 2026.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)